FindTrial
Sign In

Fructose Transporter GLUT5 Mediates Histone Lactylation Modification to Regulate Hepatocellular Carcinoma Stemness and Promote Immune Evasion A Study on Its Role and Molecular Mechanism

Fructose Transporter GLUT5 Mediates Histone Lactylation Modification to Regulate Hepatocellular Carcinoma Stemness and Promote Immune Evasion A Study on Its Role and Molecular Mechanism

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114889
Enrollment
Unknown
Registered
2025-12-18
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Observation group:None

Sponsors

Ningbo First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age >=18 years; 2.Pathological diagnosis: Primary hepatocellular carcinoma (HCC); 3.Radical resection; 4.Complete clinical records: preoperative imaging, postoperative pathology reports;

Exclusion criteria

Exclusion criteria: 1.Metastatic liver cancer, cholangiocarcinoma (ICC), mixed-type hepatocellular carcinoma; 2.Area of necrosis in cryopreserved tissue >30% (confirmed by HE staining); 3.Received preoperative chemotherapy/radiotherapy/targeted therapy/immunotherapy; 4.Lack of core data such as TNM staging and differentiation grade; 5.The patient refused specimen collection;

Design outcomes

Primary

MeasureTime frame
Histone acylation modification (H3K18la);GLUT5, PD-L1, stem cell markers (CD133/SOX2/OCT4);—

Countries

China

Contacts

Public ContactCao Qing

Ningbo First Hospital

wxyj20007@163.com+86 134 2936 4390

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026